145 related articles for article (PubMed ID: 37817914)
1. Hepatectomy After Conversion Therapy with Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitors and Anti-PD-1 Antibodies for Initially Unresectable Hepatocellular Carcinoma.
Yu B; Zhang N; Feng Y; Zhang Y; Zhang T; Wang L
J Hepatocell Carcinoma; 2023; 10():1709-1721. PubMed ID: 37817914
[TBL] [Abstract][Full Text] [Related]
2. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience.
Luo L; Xiao Y; Zhu G; Huang A; Song S; Wang T; Ge X; Xie J; Deng W; Hu Z; Wen W; Mei H; Wan R; Shan R
Front Oncol; 2022; 12():1004652. PubMed ID: 36237309
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.
Yu B; Zhang N; Feng Y; Zhang Y; Zhang T; Wang L
J Hepatocell Carcinoma; 2023; 10():1735-1748. PubMed ID: 37822726
[TBL] [Abstract][Full Text] [Related]
4. Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma.
Zhu XD; Huang C; Shen YH; Xu B; Ge NL; Ji Y; Qu XD; Chen L; Chen Y; Li ML; Zhu JJ; Tang ZY; Zhou J; Fan J; Sun HC
Ann Surg Oncol; 2023 May; 30(5):2782-2790. PubMed ID: 36178565
[TBL] [Abstract][Full Text] [Related]
5. Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations.
Zhu XD; Huang C; Shen YH; Ji Y; Ge NL; Qu XD; Chen L; Shi WK; Li ML; Zhu JJ; Tan CJ; Tang ZY; Zhou J; Fan J; Sun HC
Liver Cancer; 2021 Jul; 10(4):320-329. PubMed ID: 34414120
[TBL] [Abstract][Full Text] [Related]
6. Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kinase inhibitor and anti-PD-1 antibody: a retrospective multicenter study of 83 patients.
Lin KY; Lin ZW; Chen QJ; Luo LP; Zhang JX; Chen JH; Wang K; Tai S; Zhang ZB; Wang SF; Zhang JY; You WY; Wang B; You PH; Lin KC; Yang T; Zeng YY
Hepatol Int; 2023 Dec; 17(6):1477-1489. PubMed ID: 37382760
[TBL] [Abstract][Full Text] [Related]
7. Safety and Survival Outcomes of Liver Resection following Triple Combination Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma.
Long Y; Huang J; Liao J; Zhang D; Huang Z; He X; Zhang L
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136422
[TBL] [Abstract][Full Text] [Related]
8. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma.
Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Xu HF; Gao QZ; Yang RJ
Immunotherapy; 2021 Dec; 13(17):1395-1405. PubMed ID: 34607482
[TBL] [Abstract][Full Text] [Related]
9. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
Zhang W; Tong S; Hu B; Wan T; Tang H; Zhao F; Jiao T; Li J; Zhang Z; Cai J; Ye H; Wang Z; Chen S; Wang Y; Li X; Wang F; Cao J; Tian L; Zhao X; Chen M; Wang H; Cai S; Hu M; Bai Y; Lu S
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730273
[TBL] [Abstract][Full Text] [Related]
10. Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study.
Zhang J; Zhang X; Mu H; Yu G; Xing W; Wang L; Zhang T
Front Oncol; 2021; 11():729764. PubMed ID: 34868921
[TBL] [Abstract][Full Text] [Related]
11. Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma.
Long T; Yang Z; Zeng H; Wu W; Hu Z; Yang Z; Hu D; Zhou Z; Chen M; Zhang Y
J Hepatocell Carcinoma; 2023; 10():1849-1859. PubMed ID: 37881221
[TBL] [Abstract][Full Text] [Related]
12. Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma.
Pan Y; Mei J; Chen J; Zhang D; Wang J; Wang X; Yi M; Zhou Z; Zhang Y; Chen M; Guo R; Xu L
Ann Surg Oncol; 2022 Mar; 29(3):2016-2029. PubMed ID: 34637058
[TBL] [Abstract][Full Text] [Related]
13. Survival benefit of neoadjuvant hepatic arterial infusion chemotherapy followed by hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus.
Hu Z; Yang Z; Wang J; Fu Y; Hu Z; Zhou Z; Chen M; Zhang Y
Front Pharmacol; 2023; 14():1223632. PubMed ID: 37799969
[No Abstract] [Full Text] [Related]
14. Development and validation of prognostic nomograms for large hepatocellular carcinoma after HAIC.
Yao W; Wei R; Jia J; Li W; Zuo M; Zhuo S; Shi G; Wu P; An C
Ther Adv Med Oncol; 2023; 15():17588359231163845. PubMed ID: 37113732
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study.
Yi Y; Sun BY; Weng JL; Zhou C; Zhou CH; Cai MH; Zhang JY; Gao H; Sun J; Zhou J; Fan J; Ren N; Qiu SJ
Front Oncol; 2022; 12():1046584. PubMed ID: 36505772
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.
Ye JZ; Chen JZ; Li ZH; Bai T; Chen J; Zhu SL; Li LQ; Wu FX
World J Gastroenterol; 2017 Nov; 23(41):7415-7424. PubMed ID: 29151695
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant hepatic arterial infusion chemotherapy after radical hepatectomy for hepatocellular carcinoma--results of long-term follow-up.
Asahara T; Itamoto T; Katayama K; Ono E; Dohi K; Nakanishi T; Kitamoto M; Azuma K; Ito K
Hepatogastroenterology; 1999; 46(26):1042-8. PubMed ID: 10370664
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent hepatocellular carcinoma.
Zhang Z; Jiao T; Li J; Hu B; Zhang W; Wang Z; Wan T; Wang Y; Lu S
World J Surg Oncol; 2023 Feb; 21(1):53. PubMed ID: 36803872
[TBL] [Abstract][Full Text] [Related]
19. Laparoscopic Hepatectomy versus Open Hepatectomy After Conversion Therapy Using Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy for Patients with Initially Unresectable Hepatocellular Carcinoma.
Yang Z; Hu Z; Fu Y; Hu D; Zhou Z; Chen M; Pan Y; Zhang Y
J Hepatocell Carcinoma; 2023; 10():1157-1167. PubMed ID: 37497428
[TBL] [Abstract][Full Text] [Related]
20. Hepatic Arterial Infusion Chemotherapy as a Timing Strategy for Conversion Surgery to Treat Hepatocellular Carcinoma: A Single-Center Real-World Study.
Wang J; Zheng Z; Wu T; Li W; Wang J; Pan Y; Peng W; Hu D; Hou J; Xu L; Zhang Y; Chen M; Zhang R; Zhou Z
J Hepatocell Carcinoma; 2022; 9():999-1010. PubMed ID: 36132426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]